157 related articles for article (PubMed ID: 20179984)
1. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
[No Abstract] [Full Text] [Related]
2. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Sai K; Saito Y; Sakamoto H; Shirao K; Kurose K; Saeki M; Ozawa S; Kaniwa N; Hirohashi S; Saijo N; Sawada J; Yoshida T
Cancer Lett; 2008 Mar; 261(2):165-71. PubMed ID: 18082937
[TBL] [Abstract][Full Text] [Related]
3. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q
Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720
[TBL] [Abstract][Full Text] [Related]
4. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
6. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y; Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Araki K; Ichikawa W; Miya T; Narabayashi M; Kawara K; Sugiyama M; Hirose T; Ando Y; Sasaki Y
Ann Oncol; 2008 Dec; 19(12):2089-90. PubMed ID: 18953066
[No Abstract] [Full Text] [Related]
7. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
8. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
Cheng L; Li M; Hu J; Ren W; Xie L; Sun ZP; Liu BR; Xu GX; Dong XL; Qian XP
Cancer Chemother Pharmacol; 2014 Mar; 73(3):551-60. PubMed ID: 24448639
[TBL] [Abstract][Full Text] [Related]
9. Insights, challenges, and future directions in irinogenetics.
Kim TW; Innocenti F
Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
[TBL] [Abstract][Full Text] [Related]
10. UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.
Mani S
AAPS PharmSci; 2001; 3(3):3. PubMed ID: 11783425
[No Abstract] [Full Text] [Related]
11. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
12. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
14. Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Han FF; Guo CL; Yu D; Zhu J; Gong LL; Li GR; Lv YL; Liu H; An GY; Liu LH
Cancer Chemother Pharmacol; 2014 Apr; 73(4):779-88. PubMed ID: 24519753
[TBL] [Abstract][Full Text] [Related]
15. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
[TBL] [Abstract][Full Text] [Related]
16. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
17. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
[TBL] [Abstract][Full Text] [Related]
18. Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Ichikawa W; Araki K; Fujita K; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Kodama K; Sunakawa Y; Narabayashi M; Ando Y; Akiyama Y; Kawara K; Sasaki Y
J Natl Cancer Inst; 2008 Feb; 100(3):224-5; author reply 225. PubMed ID: 18230796
[No Abstract] [Full Text] [Related]
19. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
